Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.132
-0.006 (-4.43%)
At close: Jan 17, 2025, 4:00 PM
0.130
-0.002 (-1.22%)
After-hours: Jan 17, 2025, 7:59 PM EST
Aditxt Employees
Aditxt had 47 employees as of December 31, 2023. The number of employees decreased by 14 or -22.95% compared to the previous year.
Employees
47
Change (1Y)
-14
Growth (1Y)
-22.95%
Revenue / Employee
$4,513
Profits / Employee
-$983,995
Market Cap
1.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ADTX News
- 7 days ago - Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Business Wire
- 5 weeks ago - Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Business Wire
- 2 months ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 2 months ago - Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares - Business Wire
- 2 months ago - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders - Business Wire
- 2 months ago - Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Business Wire
- 2 months ago - Evofem Secures Investor Support for Proposed Merger through Voting Agreements - PRNewsWire
- 2 months ago - Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - Business Wire